Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACT-001 CAR-NK cell
- Development stage
- Unknown
- Lead developer
- Acellytron Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ACT-001 CAR-NK cell is an allogeneic, bispecific chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by RenJi Hospital in collaboration with Acellytron Therapeutics. The therapy consists of engineered NK cells that express a bispecific CAR targeting two distinct antigens: B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D). Both antigens are highly expressed on the surface of malignant plasma cells in multiple myeloma. By targeting two antigens simultaneously, ACT-001 aims to reduce the risk of relapse due to antigen escape and enhance the depth of clinical response. It is currently under investigation in an exploratory clinical trial (NCT06594211) for patients with relapsed or refractory multiple myeloma.
- Other names
- allogeneic anti-BCMA/GPRC5D bispecific CAR-NK cellsanti-BCMA/GPRC5D bispecific CAR-NK cells
02
Targets
GPRC5DKLRD1 (CD94/NKG2A complex)BCMA (B-cell maturation antigen)KIR (Killer-cell immunoglobulin-like receptors)NKG2D (Natural killer group 2 member D receptor)CD226 (DNAX accessory molecule 1)
Beyond the preview
Go deeper on ACT-001 CAR-NK cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT-001 CAR-NK cell.